NeurAxis, Inc.

NRXS

US64134X2018

Medical Equipment, Supplies & Distribution

Delayed Nyse Other stock markets 09:33:13 2024-06-21 am EDT			5-day change	1st Jan Change
2.75 ^USD	+1.85%		-7.41%	+3.00%

Jun. 07	NeurAxis Submits Application to FDA to Expand IB-Stim Label	MT
May. 22	Earnings Flash (NRXS) NEURAXIS Posts Q1 Revenue $646,635	MT

Neuraxis, Inc. Provides Earnings Guidance for Late 2024 and 2025

May 22, 2024 at 08:00 am EDT

NeurAxis, Inc. provided earnings guidance for late 2024 and 2025 . Given the company's recent success with new payor coverage, the company expects revenue to increase in late 2024 and into 2025.

Latest news about NeurAxis, Inc.

NeurAxis Submits Application to FDA to Expand IB-Stim Label	Jun. 07	MT
Earnings Flash (NRXS) NEURAXIS Posts Q1 Revenue $646,635	May. 22	MT
Neuraxis, Inc. Provides Earnings Guidance for Late 2024 and 2025	May. 22	CI
NeurAxis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 20	CI
NeurAxis, Inc. Terminates Dan Clarence as Chief Operating Officer	Apr. 16	CI
NeurAxis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 09	CI
NeurAxis, Inc. Provides Revenue Guidance in Late 2024 and into 2025	Apr. 09	CI
NeurAxis, Inc. Announces IB-Stim Results from A Large, Pediatric, Multi-Center Registry	Mar. 27	CI
Neuraxis, Inc. Appoints Kristin Ferge to the Board	Mar. 11	CI
Top Premarket Decliners	Feb. 12	MT
Certain Common Stock of NeurAxis, Inc. are subject to a Lock-Up Agreement Ending on 5-FEB-2024.	Feb. 04	CI
Certain Preferred Stock of NeurAxis, Inc. are subject to a Lock-Up Agreement Ending on 5-FEB-2024.	Feb. 04	CI
Certain Options of NeurAxis, Inc. are subject to a Lock-Up Agreement Ending on 5-FEB-2024.	Feb. 04	CI
Certain Warrants of NeurAxis, Inc. are subject to a Lock-Up Agreement Ending on 5-FEB-2024.	Feb. 04	CI
NeurAxis Names Timothy Henrichs Finance Chief	Jan. 31	MT
NeurAxis, Inc. Announces Resignation of Timothy Henrichs as Independent Director	Jan. 31	CI
NeurAxis, Inc. Appoints Timothy Henrichs as Chief Financial Officer, Effective February 5, 2024	Jan. 31	CI
NeurAxis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
NeurAxis, Inc. announced that it expects to receive $3 million in funding from Flagstaff International, Inc	Nov. 08	CI
NeurAxis Signs Option Deal for University of Michigan's Rectal Expulsion Device	Nov. 08	MT
NeurAxis, Inc. Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal Device	Nov. 08	CI
NeurAxis, Inc. Announces Results of Comparative Study of IB-Stim and Standard Medical Therapy in Adolescents with Functional Abdominal Pain Disorders	23-09-26	CI
Earnings Flash (NRXS) NEURAXIS Posts Q2 Revenue $646,000	23-09-21	MT
NeurAxis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-21	CI
NeurAxis, Inc.(NYSEAM:NRXS) added to S&P TMI Index	23-09-18	CI

Neuraxis, Inc. is a medical technology company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It is engaged in advancing science with its IB-Stim therapy, based on its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, which was developed internally by the Company. The Company's first product, IB-Stim, is a PENFS system intended to be used in patients 11-18 years of age with functional abdominal pain associated with IBS. The IB-Stim is intended to be used for 120 hours per week for three consecutive weeks, and not to exceed four weeks, through application to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the reduction of pain when combined with other therapies for IBS. Other indications in its pipeline are comprised of functional nausea in children, post-concussion syndrome in children, and cyclic vomiting syndrome in children.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-09-18 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.7 USD

Average target price

7.5 USD

Spread / Average Target

+177.78%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Medical Equipment

	1st Jan change	Capi.
NEURAXIS, INC.	+3.00%	17.95M
SHOCKWAVE MEDICAL	+75.69%	12.57B
MASIMO CORPORATION	+10.39%	6.92B
PENUMBRA, INC.	-28.98%	6.8B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+11.54%	5.32B
GETINGE AB	-20.60%	4.63B
APT MEDICAL INC.	+10.66%	3.94B
INARI MEDICAL, INC.	-27.77%	2.68B
NOVOCURE LIMITED	+29.54%	2.06B
SKAN GROUP AG	-1.98%	2.01B

Medical Equipment

NeurAxis, Inc.

Equities

NRXS

US64134X2018

Medical Equipment, Supplies & Distribution

Neuraxis, Inc. Provides Earnings Guidance for Late 2024 and 2025

Latest news about NeurAxis, Inc.

Chart NeurAxis, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

Quarterly revenue - Rate of surprise

Sector Medical Equipment